Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Apremilast Tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults

NCT01634178
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

NCT06586112
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Envudeucitinib, Apremilast, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
55
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 17, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

NCT02087943
View directory record Official record
Conditions
Dermatitis, Atopic Dermatitis
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

NCT00866359
View directory record Official record
Conditions
Behcet Syndrome
Interventions
Apremilast (CC-10004), Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Jacksonville, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

NCT03000309
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 17, 2026, 9:22 AM EDT
Withdrawn Phase 2 Interventional

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

NCT01200264
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
apremilast
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

NCT01561963
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apremilast, Rifampin Oral Capsules, Rifampin IV Solution
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

NCT00773734
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
20
States / cities
Fresno, California • Los Angeles, California • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

NCT02236988
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Immediate Release, Apremilast Modified Release 1, Apremilast Modified Release 2, Apremilast Modified Release 3, Apremilast Modified Release 4, Apremilast Modified Release 5, Apremilast Modified Release 6, Apremilast Modified Release 8, Apremilast Modified Release 9, Apremilast Modified Release 11, Apremilast Modified Release 12, Apremilast Modified Release 13, Apremilast Modified Release 14
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 17, 2026, 9:22 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01041625
View directory record Official record
Conditions
Lichen Planus
Interventions
Apremilast (CC-10004)
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Sep 17, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

NCT06088199
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 9:22 AM EDT